Zoe Quandt, MD

Title(s)Assistant Professor, Diabetes Center
SchoolSchool of Medicine
Address35 Medical Center Way, #1102
San Francisco CA 94143
Phone415-353-2350
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFFellowshipEndocrinology and Diabetes
    Stanford Hospital and ClinicsResidencyInternal Medicine
    UCSFMDMedical School
    UC BerkeleyMSHealth and Medical Sciences
    Brown UniversityBABiology

    Collapse Overview 
    Collapse Overview
    Dr. Quandt is an endocrinologist at UCSF and the San Francisco VA with particular interest in endocrine autoimmune disease like type 1 diabetes and endocrine complications of cancer treatments, particularly immunotherapy. She does clinical and translational research trying to better understand who gets these complications and why. She is the clinical lead for adults eligible for teplizumab, an immunotherapy approved to delay the onset of type 1 diabetes.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. 67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity. Annals of Oncology. 2024 Sep 1; 35:s240-s241. Thorball TC, Quandt QZ, Saha SA, Yao YL, Midda MP, Xu XY, Bejan BC, Hodel HF, Stravodimou SA, Shearer-Kang SE, Aldrich AM, Philips PE, Liu LG, Schoenfeld SA, Johnson JD, Ziv ZE, Fellay FJ, Mohindra MR, Balko BJ, Chandler CG. .
      View in: Publisher Site   Mentions:
    2. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harb Perspect Med. 2024 Jul 22. Quandt Z, Perdigoto A, Anderson MS, Herold KC. PMID: 39038853.
      View in: PubMed   Mentions:    Fields:    
    3. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2024 Jun 24; 2(1):46. Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. PMID: 39516257; PMCID: PMC11524064.
      View in: PubMed   Mentions:
    4. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. medRxiv. 2024 Jun 11. Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Princess Margaret Lung Group, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. PMID: 38947092; PMCID: PMC11213033.
      View in: PubMed   Mentions:
    5. Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):584-584. Nanda NR, Cohen CR, Quandt QZ, Basu BA, Yau YC, Chien CA, Pusztai PL, Han HH, Stringer-Reasor SE, Isaacs IC, Hershman HD, Shatsky SR, Perlmutter PJ, Yee YD, DeMichele DA, van 't Veer vL, Hylton HN, Esserman EL, Rugo RH. .
      View in: Publisher Site   Mentions:
    6. HLA associations with immunotherapy related endocrine toxicity. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):2516-2516. Quandt QZ, Thorball TC, Middha MP, Johnson JD, Bejan BC, Yao YL, Xu XY, Hodel HF, Stravodimou SA, Shearer-Kang SE, Liu LG, Aldrich AM, Schoenfeld SA, Ziv ZE, Phillips PE, Fellay FJ, Bergmann BE, Chandler CG, Balko BJ, Saha SA. .
      View in: Publisher Site   Mentions:
    7. Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):10600-10600. Fergus FK, Middha MP, Quandt QZ, Shieh SY, Basu BA, Sayaman SR, Pohlmann PP, Yee YD, Shatsky SR, Isaacs IC, Campbell CM, Hirst HG, Brown Swigart BL, van 't Veer vL, Ziv ZE, Esserman EL. .
      View in: Publisher Site   Mentions:
    8. Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Cancer Research. 2024 May 2; 84(9_Supplement):ps14-03-ps14-03. Jacob JS, Fisch FS, Face FC, Huppert HL, Quandt QZ, Quintal QL, Melisko MM, Majure MM, Chien CJ, Blaes BA, Rugo RH. .
      View in: Publisher Site   Mentions:
    9. Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study. Cancers (Basel). 2024 Apr 25; 16(9). Duvalyan E, Brondfield S, Rushakoff RJ, Anderson MS, Quandt Z. PMID: 38730614; PMCID: PMC11083325.
      View in: PubMed   Mentions:
    10. Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency. J Exp Med. 2024 Jun 03; 221(6). Johnson MB, Ogishi M, Domingo-Vila C, De Franco E, Wakeling MN, Imane Z, Resnick B, Williams E, Galão RP, Caswell R, Russ-Silsby J, Seeleuthner Y, Rinchai D, Fagniez I, Benson B, Dufort MJ, Speake C, Smithmyer ME, Hudson M, Dobbs R, EXE-T1D consortium, Quandt Z, Hattersley AT, Zhang P, Boisson-Dupuis S, Anderson MS, Casanova JL, Tree TI, Oram RA. PMID: 38634869; PMCID: PMC11032109.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. Nat Commun. 2024 Mar 26; 15(1):2568. Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. PMID: 38531883; PMCID: PMC10966072.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score. Cancer Research. 2024 Mar 22; 84(6_Supplement):3460-3460. Middha MP, Thummalapalli TR, Quandt QZ, Group GP, Gubens GM, Lovly LC, Liu LG, Aldrich AM, Schoenfeld SA, Ziv ZE. .
      View in: Publisher Site   Mentions:
    13. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer. 2024 Jan 31; 10(1):12. Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. PMID: 38297009; PMCID: PMC10831089.
      View in: PubMed   Mentions: 2  
    14. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. PMID: 38027216; PMCID: PMC10643762.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. Oncologist. 2023 10 03; 28(10):e950-e959. Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z. PMID: 37335906; PMCID: PMC10546826.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. medRxiv. 2023 Sep 13. Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. PMID: 37292751; PMCID: PMC10246037.
      View in: PubMed   Mentions:
    17. Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects? Front Endocrinol (Lausanne). 2023; 14:1268402. Gomes-Lima CJ, Zhou W, Quandt Z. PMID: 37766679; PMCID: PMC10520552.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having. Cancer. 2023 09 15; 129(18):2769-2770. Sharon E, Othus M, Quandt ZE. PMID: 37439269; PMCID: PMC11060182.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. The cognitive load of inpatient consults involving immune-related adverse events. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):11033-11033. Brondfield BS, Silverstein SJ, de Dios dK, Quandt QZ. .
      View in: Publisher Site   Mentions:
    20. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e24091-e24091. Jacob JS, Quandt QZ, Melisko MM, Majure MM, Chien CA, Blaes BA, Heditsian HD, Esserman EL, Rugo RH. .
      View in: Publisher Site   Mentions:
    21. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. J Endocr Soc. 2023 Feb 09; 7(4):bvad012. Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U. PMID: 36860908; PMCID: PMC9969737.
      View in: PubMed   Mentions: 8  
    22. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol. 2023 05; 41(5):717-727. Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. PMID: 36593395; PMCID: PMC10188358.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    23. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes. 2023 01 01; 72(1):59-70. Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL. PMID: 35709010; PMCID: PMC9797316.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    24. Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq. Elife. 2022 10 27; 11. Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY, Tagi VM, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kämpe O, Dobbs K, Delmonte OM, Bacchetta R, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL. PMID: 36300623; PMCID: PMC9711525.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    25. Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP). Journal of Clinical Oncology. 2022 Sep 30; 40(28_suppl):422-422. Gallagher GE, Moore MH, Lacouture LM, Dent DS, Farooki FA, Goncalves GM, Isaacs IC, Johnston JA, Juric JD, Quandt QZ, Spring SL, Berman BB, Decker DM, Hortobagyi HG, Kaffenberger KB, Kwong KB, Pluard PT, Rao RR, Schwartzberg SL, Broder BM. .
      View in: Publisher Site   Mentions:
    26. Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022 09 08; 7(17). Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. PMID: 35925682; PMCID: PMC9536276.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    27. Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):2668-2668. Quandt QZ, Hill HV, Dib DJ, Burian BJ, Tessler TS, Naqash NA, Anderson AM, Othus OM, Sharon SE. .
      View in: Publisher Site   Mentions:
    28. 189-OR: Immune-Profiling of Pancreatic Tissue Affected by Immune Checkpoint Inhibitor–Induced Diabetes (CPI-D). Diabetes. 2022 Jun 1; 71(Supplement_1). QUANDT QZ, YOUNG YA, BARLOW BG, DONG DS, SMITH SJ, KUSMARTSEVA KI, BRUSKO BT, COOPER CS, ANDERSON AM. .
      View in: Publisher Site   Mentions:
    29. Evaluating survival following severe immune-related adverse events requiring hospitalization. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):2666-2666. Wright WF, Kim KD, Silverstein SJ, Wang WM, de Dios dK, Young YA, Quandt QZ, Brondfield BS. .
      View in: Publisher Site   Mentions:
    30. Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq. bioRxiv. 2022 Mar 24. Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Mandel-Brehm C, Miao B, Sowa G, Zorn K, Chan AY, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kampe O, Dobbs K, Delmonte OM, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL. PMID: 35350199; PMCID: PMC8963698.
      View in: PubMed   Mentions:
    31. Patient-Centered Diabetes Care of Cancer Patients. Curr Diab Rep. 2021 12 13; 21(12):62. Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME. PMID: 34902069.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140. Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E. PMID: 34244291; PMCID: PMC8815444.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    33. Case 20: Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes. . 2021 Jan 1; 80-82. Quandt QZ, Mehta MP, Tsai TK, Hsiao HV, Rushakoff RR. .
      View in: Publisher Site   Mentions:
    34. Case 21: Checkpoint Inhibitor–Induced Diabetes. . 2021 Jan 1; 83-85. Mehta MP, Quandt QZ, Rushakoff RR. .
      View in: Publisher Site   Mentions:
    35. Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. Annu Rev Med. 2021 01 27; 72:313-330. Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS. PMID: 32886542.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    36. Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. J Endocr Soc. 2020 Oct 01; 4(10):bvaa114. Quandt Z, Coupe C, Anderson M, Uihlein A, Young A. PMID: 32964173; PMCID: PMC7491923.
      View in: PubMed   Mentions: 1  
    37. Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. Elife. 2020 05 15; 9. Vazquez SE, Ferré EM, Scheel DW, Sunshine S, Miao B, Mandel-Brehm C, Quandt Z, Chan AY, Cheng M, German M, Lionakis M, DeRisi JL, Anderson MS. PMID: 32410729; PMCID: PMC7228772.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    38. SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis. Journal of the Endocrine Society. 2020 May 8; 4(Supplement_1):sun-298-. Quandt QZ, Kim KS, Villanueva-Meyer VJ, Coupe CC, Tyrrell TJ, Bluestone BJ, Anderson AM, Masharani MU. .
      View in: Publisher Site   Mentions:
    39. SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Quandt QZ, Trupin TL, Evans EM, Schmajuk SG, Anderson AM, Bluestone BJ, Jinoos JY. .
      View in: Publisher Site   Mentions:
    40. SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus. Journal of the Endocrine Society. 2020 May 8; 4(Supplement_1):sat-667-. Quandt QZ, Tsai TK, Hsiao HV. .
      View in: Publisher Site   Mentions:
    41. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020 05; 200(2):131-140. Quandt Z, Young A, Anderson M. PMID: 32027018; PMCID: PMC7160652.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimals
    42. Chapter 19 Thyroid Disorders During Pregnancy, Postpartum, and Lactation. Maternal-Fetal and Neonatal Endocrinology. 2020 Jan 1; 287-315. Quandt QZ, Salmeen SK, Block-Kurbisch BI. .
      View in: Publisher Site   Mentions:
    43. Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma. J Clin Invest. 2019 08 01; 129(11):4676-4681. Moore PC, Cortez JT, Chamberlain CE, Alba D, Berger AC, Quandt Z, Chan A, Cheng MH, Bautista JL, Peng J, German MS, Anderson MS, Oakes SA. PMID: 31369399; PMCID: PMC6819098.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    44. Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol. 2019 06; 7(6):421-423. Perdigoto AL, Quandt Z, Anderson M, Herold KC. PMID: 30885563.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    45. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res. 2018 12; 6(12):1445-1452. Young A, Quandt Z, Bluestone JA. PMID: 30510057; PMCID: PMC6281171.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimals
    46. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 08; 67(8):1471-1480. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. PMID: 29937434; PMCID: PMC6054443.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansAnimals
    47. Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):4087-4087. Kelley KR, Mitchell ME, Behr BS, Hwang HJ, Keenan KB, Umetsu US, Gordan GJ, Ko KA, Cinar CP, Atreya AC, Van Loon VK, Weber WT, Ngo NZ, Quandt QZ, Liu LC, Venook VA, Fong FL. .
      View in: Publisher Site   Mentions:
    48. Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). Journal of Clinical Oncology. 2018 Feb 1; 36(4_suppl):386-386. Kelley KR, Mitchell ME, Behr BS, Hwang HJ, Keenan KB, Cheung CA, Gordan GJ, Ko KA, Cinar CP, Atreya AC, Van Loon VK, Weber WT, Ngo NZ, Quandt QZ, Liu LC, Venook VA, Fong FL. .
      View in: Publisher Site   Mentions:
    49. Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. Mol Clin Oncol. 2017 Apr; 6(4):589-592. Serling-Boyd N, Quandt Z, Allaudeen N. PMID: 28413674; PMCID: PMC5374943.
      View in: PubMed   Mentions: 11  
    50. The association of alcohol consumption with mammographic density in a multiethnic urban population. BMC Cancer. 2015; 15:1094. Quandt Z, Flom JD, Tehranifar P, Reynolds D, Terry MB, McDonald JA. PMID: 25777420; PMCID: PMC4374505.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    51. Association of age, stature, and education with ocular dimensions in an older white population. Arch Ophthalmol. 2009 Jan; 127(1):88-93. Lee KE, Klein BE, Klein R, Quandt Z, Wong TY. PMID: 19139346; PMCID: PMC2725427.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    Zoe's Networks
    Concepts (109)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (46)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.